A 58-year-old man on atorvastatin monotherapy has LDL-C of 95 mg/dL but remains at high cardiovascular risk. His physician adds ezetimibe. Which mechanism best distinguishes ezetimibe's action from that of statins in lowering cholesterol?

Explanation

## Mechanisms of Ezetimibe vs Statins: A Fundamental Distinction ### Site and Mechanism of Action **Key Point:** Statins and ezetimibe act at *different anatomical sites* and via *different molecular mechanisms*. This distinction is high-yield and frequently tested in NEET PG. | Property | Statins | Ezetimibe | |----------|---------|----------| | **Site of action** | Hepatocyte (liver) | Intestinal epithelium (brush border) | | **Target molecule** | HMG-CoA reductase enzyme | NPC1L1 transporter protein | | **Effect** | Inhibits *de novo* cholesterol synthesis | Blocks dietary cholesterol *absorption* | | **LDL-C reduction** | 25–55% | 15–20% | | **Mechanism of LDL↓** | ↑ LDL receptor expression (via SREBP-2) | Reduced hepatic cholesterol pool → ↑ LDL receptor | | **Synergy** | Additive when combined | Yes — complementary sites | ### Why Ezetimibe and Statins Are Complementary **High-Yield:** Ezetimibe reduces the *intestinal pool* of cholesterol available for absorption, while statins reduce the *hepatic synthesis* of cholesterol. When combined, they achieve synergistic LDL lowering (additional 15–20% reduction beyond statin monotherapy). **Clinical Pearl:** The NPC1L1 transporter on the intestinal brush border is the molecular target of ezetimibe. Genetic loss-of-function mutations in NPC1L1 result in very low cholesterol absorption and naturally low LDL-C levels — proof that blocking this transporter is effective. ### Mnemonic for Statin vs Ezetimibe **STATIN = Synthesis Inhibitor (liver)** **EZETIMIBE = Enteric absorption blocker (intestine)** [cite:KD Tripathi 8e Ch 28]